Interviews

Gary Lyman, MD, MPH, co-director of the Hutchinson Institute for Cancer Outcomes Research (HICOR) discusses the inspiration, key findings, and overall goals of HICOR’s first-of-its-kind community cancer care report, “Community Cancer Care in Washington State: Quality and Cost Report.”
Chadi Nabhan, MD, MBA, FACP, shares his insights about the anticipated clinical and economic impact of newly available treatments for AML and discusses how payers and clinical pathways developers are likely to respond to the changing landscape for this disease.
Nathan R Handley, MD, explains the extent to which unplanned acute hospital care is a concern for the health care system and ways in which care coordination and clinical pathways can help decrease unnecessary spending.
Richard Kane, MIPP, MA, and Josh Seidman, PhD, MHS, both with Avalere Health, share their thoughts on the intricacies of the MACRA Merit-Based Incentive Payment System and the risk practices must accept when transitioning to the Oncology Care Model.
Ray D Page, DO, PhD, addresses how including drug costs in bundled payments places oncology practices at the uncontrollable probabilistic risk of patient case mixes.
Bijal Shah-Manek, BPharm, PhD, discusses oncologist perceptions of drug affordability and ways to improve existing value frameworks.
Adam M Brufsky, MD, PhD, discusses some of the key topics and data for examining the clinical and cost implications of HER-positive breast cancer care in the value-based care era.
Dawn Holcombe, MBA, FACMPE, ACHE, explains why private payers are making the transition from traditional reimbursement models to value-based models at a slow pace and how OCM performance results may impact this transition.
Erin Crum, MPH, director of quality reporting, McKesson, discusses being granted approval again to participate in MIPS, what is new for 2018, and how the company is situated to support the three MIPS practice-reported categories.
Robin T Zon, MD, FACP, FASCO, and Bobby Daly, MD, MBA, discuss ASCO's recently published results of an evaluation of national pathway vendors against the Criteria for High-Quality Clinical Pathways.